Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 18;16:823–832. doi: 10.2147/OPTH.S354958

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Maekawa et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Increase in RBPMS-positive cells after NMDA injury and supplementation. (A) Representative images of RBPMS-positive RGCs 24 hours after the intravitreal injection of NMDA without supplementation or with a low- or high-dose supplement. GCL, ganglion cell layer; INL, inner nuclear layer. Scale bar: 100 µm. (B) Histogram showing the average number of RBPMS-positive cells in each group. Data represent mean ± SD (PBS, n = 8; low-dose supplement, n = 6; high-dose supplement, n = 8). *p <0.05.